See the DrugPatentWatch profile for Entresto
Does Entresto treat atrial fibrillation?
Entresto (sacubitril/valsartan) is approved for chronic heart failure, not for atrial fibrillation (AF) itself. It may affect AF risk indirectly because AF often occurs alongside heart failure and structural heart disease, but it is not an AF-specific treatment.
How could Entresto influence atrial fibrillation risk?
By improving heart failure physiology, Entresto can reduce the stresses that contribute to abnormal atrial rhythms in some patients. AF is commonly linked to conditions such as elevated filling pressures, left-atrial enlargement, and neurohormonal activation—all of which are targeted by heart-failure therapies.
Is Entresto used instead of rate-control or rhythm-control drugs for AF?
No. For AF, clinicians typically use therapies aimed at controlling heart rate (such as beta-blockers or calcium-channel blockers) or rhythm (such as antiarrhythmics), and they assess stroke prevention with anticoagulation when indicated. Entresto would generally be part of heart failure management rather than a replacement for standard AF treatment.
When might a patient with both AF and heart failure be prescribed Entresto?
Entresto is considered when a person has chronic heart failure that fits guideline-based indications, regardless of whether they also have AF. In patients with AF, doctors still manage AF-specific issues (rate/rhythm and anticoagulation) alongside heart failure treatment.
What side effects and risks matter for AF patients taking Entresto?
The key safety considerations for Entresto are those relevant to heart failure therapy, including blood pressure lowering and kidney-related effects. In people with AF, these same risks matter because low blood pressure or worsening renal function can complicate the rest of the cardiovascular regimen. Entresto also has drug-interaction considerations that must be checked alongside common AF medications.
Can Entresto be combined with anticoagulants used for AF?
In general, Entresto can be used alongside anticoagulants when there is a reason for both (heart failure plus AF). The decision is individualized based on kidney function, blood pressure, bleeding risk, and the specific anticoagulant.
What would a clinician look for before starting Entresto in someone with AF?
Doctors typically check heart failure eligibility and review blood pressure, kidney function, potassium level, and current medications to avoid interactions. If an AF patient is also taking multiple cardiovascular drugs, careful medication reconciliation is important to prevent hypotension or renal complications.
What should patients ask their cardiologist?
Patients can ask whether Entresto is being prescribed for heart failure management and, if so, how that goal connects to their AF (for example, whether it’s intended to reduce AF burden through heart failure control). They can also ask how Entresto fits with their AF plan for rate/rhythm control and stroke prevention.
Sources
No sources were provided with the question, so I can’t cite specific trial/regulatory details or guideline language here. If you share the source links or documents you’re working from (or tell me which country/guideline you mean), I can tailor the answer with precise citations.